Acquired Hemophilia A Post-COVID-19 Vaccination: A Case Report and Review
Open Access
- 4 February 2022
- journal article
- review article
- Published by Springer Nature in Cureus
- Vol. 14 (2) , e21909
Abstract
Acquired hemophilia A (AHA) is an inhibitory coagulopathy that represents a rare variant of hemorrhagic syndromes. We present a case of idiopathic AHA in a 75-year-old male patient with a cutaneous hematoma that could be attributed to a recent COVID-19 vaccination. The aim of this report is to raise awareness of a possible association between AHA and COVID-19 vaccination and to review similar reported cases and management plans to prevent the development of possible morbidity and debilitating complications. This case illustrates an exceptionally rare side effect of the COVID-19 vaccination. The advantages of obtaining the COVID-19 vaccine outweigh the risks.Keywords
This publication has 17 references indexed in Scilit:
- Acquired hemophilia A: emerging treatment optionsJournal of Blood Medicine, 2015
- Management of acquired haemophilia AHamostaseologie, 2015
- Acquired Inhibitors of Coagulation Factors: Part I—Acquired Hemophilia ASeminars in Thrombosis and Hemostasis, 2012
- Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)Journal of Thrombosis and Haemostasis, 2012
- Do proteolytic antibodies complete the panoply of the autoimmune response in acquired haemophilia A?British Journal of Haematology, 2011
- International recommendations on the diagnosis and treatment of patients with acquired hemophilia AHaematologica, 2009
- Acquired factor VIII inhibitorsBlood, 2008
- Acquired Factor VIII Inhibitors: Pathophysiology and TreatmentHematology-American Society Hematology Education Program, 2006
- Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodiesHaemophilia, 2005
- Vaccination and autoimmune disease: what is the evidence?The Lancet, 2003